Research programme - RSPO-LGR antibody therapeutics - OncoMed

Drug Profile

Research programme - RSPO-LGR antibody therapeutics - OncoMed

Alternative Names: anti RSPO3; Anti-RSPO-LGR antibodies - OncoMed

Latest Information Update: 12 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action G protein-coupled receptor antagonists; Stem cell inhibitors; Thrombospondin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Dec 2013 OncoMed Pharmaceuticals and Celgene enter into a collaboration to jointly develop and commercialise up to six OncoMed anti-cancer stem cell product candidates, including up to four programmes targeting either the RSPO-LGR pathway or an undisclosed pathway
  • 09 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)
  • 09 Apr 2013 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top